EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic value of pretreatment anemia in patients with diffuse large B-cell lymphoma treated with R-CHOP

Thi Thuy Nguyen, Thi Linh Nguyen, Minh Tri Phan, Thi Do Quyen Phan

Tạp chí Y Dược Huế · 30.04.2026 · 16 (02) · 57-62

DOI: 10.34071/jmp.2026.2.860 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tạp chí Y Dược Huế, online erschienen am 30.04.2026. Verfasst von Thi Thuy Nguyen und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. While R-CHOP is the standard of care, treatment failure remains a challenge. Pretreatment anemia is a common paraneoplastic manifestation, yet its prognostic utility in Vietnamese patients remains under-investigated. Materials and Methods: A combined prospective and retrospective study was conducted on 106 patients with CD20-positive DLBCL treated with first-line R-CHOP at Hue University of Medicine and Pharmacy Hospital, Hue Central Hospital and Da Nang Oncology Hospital from December 2022 to August 2025. Pretreatment anemia was classified according to NCI-CTCAE v5.0. Clinicopathological features, toxicity, treatment response, and survival were analyzed.

Results

The prevalence of pretreatment anemia was 32.1%, with the majority being Grade 1 (26.4%). Anemia was significantly associated with B symptoms (p=0.034) and older age (p=0.039). Regarding efficacy, non-anemic patients had approximately 12 times higher odds of responding (Odds Ratios = 11.897; 95% CI: 1.33–106.34, p = 0.014). Toxicity analysis showed a 3.8% treatment-related mortality rate due to severe infections. There was no statistically significant difference in overall survival or progression-free survival (p > 0.05).

Conclusion

Pretreatment anemia is a robust and easily accessible predictor of poor early treatment response in Vietnamese patients with DLBCL treated with R-CHOP. Anemic patients have significantly lower odds of achieving remission. While long-term survival benefits were obscured by treatment-related toxicity in this cohort, the strong link between hemoglobin levels and therapeutic efficacy suggests that anemia should be integrated into risk stratification.

Zitieren

APA

Nguyen, T. T., Nguyen, T. L., Phan, M. T., & Phan, T. D. Q. (2026). Prognostic value of pretreatment anemia in patients with diffuse large B-cell lymphoma treated with R-CHOP. Tạp chí Y Dược Huế, 16(02), 57-62. https://doi.org/10.34071/jmp.2026.2.860

Vancouver

Nguyen TT, Nguyen TL, Phan MT, Phan TDQ. Prognostic value of pretreatment anemia in patients with diffuse large B-cell lymphoma treated with R-CHOP. Tạp chí Y Dược Huế. 2026;16(02):57-62. doi:10.34071/jmp.2026.2.860

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Thi Thuy and Nguyen, Thi Linh and Phan, Minh Tri and Phan, Thi Do Quyen},
  title = {Prognostic value of pretreatment anemia in patients with diffuse large B-cell lymphoma treated with R-CHOP},
  journal = {Tạp chí Y Dược Huế},
  year = {2026},
  volume = {16},
  number = {02},
  pages = {57--62},
  doi = {10.34071/jmp.2026.2.860}
}
Kostenlos starten →